Angela Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela Cho has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Se Ik Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - Allen Gideon Tan
Department of Obstetrics and Gynecology, University of the Philippines Manila, Manila, Philippines
3 shared publications - Biswajit Dash
Department of Gynecological Oncology, Tata Memorial Hospital, HBNI University, Mumbai, India
3 shared publications - Christine Shan-Chi Chiu
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
3 shared publications - Doris R. Benavides
Department of Obstetrics and Gynecology, University of the Philippines Manila, Manila, Philippines
3 shared publications - Emiri Miyamoto
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
The real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessThe real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- Open Access
- 30 January 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (6) , 769-777
Preoperative Prediction of Prolonged Operative Time in Laparoscopic Ovarian Cystectomy Using Convolutional Neural Network-Extracted Ultrasound Image Features
- 30 January 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (6) , 769-777
Open AccessPreoperative Prediction of Prolonged Operative Time in Laparoscopic Ovarian Cystectomy Using Convolutional Neural Network-Extracted Ultrasound Image Features
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (2) , 1-19
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
Shim SH, et al. J Gynecol Oncol. 2024 Jan;35:e66. https://doi.org/10.3802/jgo.2024.35.e66
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (2) , 1-19
Open AccessMajor clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
Shim SH, et al. J Gynecol Oncol. 2024 Jan;35:e66. https://doi.org/10.3802/jgo.2024.35.e66
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (6)
Outcomes and prognostic factors of surgically treated extramammary Paget’s disease of the vulva
Cho A, et al. J Gynecol Oncol. 2023 Jul;34:e76. https://doi.org/10.3802/jgo.2023.34.e76
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (6)
Open AccessOutcomes and prognostic factors of surgically treated extramammary Paget’s disease of the vulva
Cho A, et al. J Gynecol Oncol. 2023 Jul;34:e76. https://doi.org/10.3802/jgo.2023.34.e76
- Open Access
- 31 December 2021
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 18 (2) , 117-120
Prenatal detection of Xq deletion by abnormal noninvasive prenatal screening, subsequently diagnosed by amniocentesis: A case report
Bo Ram Kim, Rina Kim, Angela Cho, Hye Sim Kang, Chul Min Park, Sung Yob Kim, and Soon Sup Shim. J Genet Med 2021;18:117-20. https://doi.org/10.5734/JGM.2021.18.2.117
- 31 December 2021
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 18 (2) , 117-120
Open AccessPrenatal detection of Xq deletion by abnormal noninvasive prenatal screening, subsequently diagnosed by amniocentesis: A case report
Bo Ram Kim, Rina Kim, Angela Cho, Hye Sim Kang, Chul Min Park, Sung Yob Kim, and Soon Sup Shim. J Genet Med 2021;18:117-20. https://doi.org/10.5734/JGM.2021.18.2.117
- 19 April 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 304 (4) , 1055-1063
Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Purpose The primary objective of our study was to investigate the effectiveness and safety of olaparib maintenance therapy in patients with BRCA-mutated recurrent ovarian cancer in daily practice. The secondary objective of this study was to identify prognostic factors associated with prolonged progression-free survival (PFS) in such patients. Methods We conducted a retrospective analysis of 40 patients who received olaparib maintenance treatment. Data on clinicopathological factors, oncological outcomes, and adverse events were obtained from medical records and analyzed. Results All patients had high-grade serous recurrent ovarian cancer with BRCA mutation and achieved complete or partial response to the most recent platinum-based chemotherapy. After a median follow-up of 14.3 months, the median PFS was 23.7 months (95% confidence interval, 14.1–33.4); however, the median overall survival was not reached. In the log-rank test, the PFS was significantly longer for patients with most recent platinum-free interval (PFI) ≥ 12 months, complete response to the last platinum-based chemotherapy, and less than three lines of previous chemotherapy (p = 0.005, p = 0.016, and p = 0.023, respectively). Most hematologic and non-hematologic adverse events were of grade 1 or 2, and the common adverse events were mostly related to myelosuppression. Conclusion Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.
- 19 April 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 304 (4) , 1055-1063
Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Purpose The primary objective of our study was to investigate the effectiveness and safety of olaparib maintenance therapy in patients with BRCA-mutated recurrent ovarian cancer in daily practice. The secondary objective of this study was to identify prognostic factors associated with prolonged progression-free survival (PFS) in such patients. Methods We conducted a retrospective analysis of 40 patients who received olaparib maintenance treatment. Data on clinicopathological factors, oncological outcomes, and adverse events were obtained from medical records and analyzed. Results All patients had high-grade serous recurrent ovarian cancer with BRCA mutation and achieved complete or partial response to the most recent platinum-based chemotherapy. After a median follow-up of 14.3 months, the median PFS was 23.7 months (95% confidence interval, 14.1–33.4); however, the median overall survival was not reached. In the log-rank test, the PFS was significantly longer for patients with most recent platinum-free interval (PFI) ≥ 12 months, complete response to the last platinum-based chemotherapy, and less than three lines of previous chemotherapy (p = 0.005, p = 0.016, and p = 0.023, respectively). Most hematologic and non-hematologic adverse events were of grade 1 or 2, and the common adverse events were mostly related to myelosuppression. Conclusion Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.